United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $582.76, for a total value of $5,536,220.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $189,072,402.68. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
United Therapeutics Stock Down 0.8%
Shares of UTHR opened at $586.48 on Thursday. The company has a market cap of $25.15 billion, a PE ratio of 20.98, a P/E/G ratio of 4.26 and a beta of 0.49. The business has a fifty day moving average of $524.26 and a 200 day moving average of $529.41. United Therapeutics Corporation has a 52-week low of $415.26 and a 52-week high of $609.35.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analysts’ expectations of $804.65 million. During the same quarter in the previous year, the business posted $6.41 earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. As a group, research analysts anticipate that United Therapeutics Corporation will post 26.07 earnings per share for the current fiscal year.
United Therapeutics announced that its board has initiated a stock buyback program on Thursday, October 22nd that permits the company to repurchase $2 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
Analyst Upgrades and Downgrades
Several equities analysts recently commented on UTHR shares. JPMorgan Chase & Co. cut their price target on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a report on Wednesday. Leerink Partners boosted their target price on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $850.00 target price on shares of United Therapeutics in a research note on Monday. Bank of America reduced their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Royal Bank Of Canada decreased their price target on United Therapeutics from $708.00 to $697.00 and set an “outperform” rating for the company in a research note on Thursday, October 22nd. Twelve research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $667.07.
View Our Latest Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
Several large investors have recently added to or reduced their stakes in the stock. MGO One Seven LLC raised its stake in shares of United Therapeutics by 4.5% during the third quarter. MGO One Seven LLC now owns 953 shares of the biotechnology company’s stock valued at $516,000 after acquiring an additional 41 shares in the last quarter. State of Wyoming purchased a new stake in shares of United Therapeutics in the third quarter valued at approximately $141,000. China Universal Asset Management Co. Ltd. grew its stake in United Therapeutics by 19.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,076 shares of the biotechnology company’s stock worth $4,376,000 after purchasing an additional 1,321 shares in the last quarter. BOKF NA grew its stake in United Therapeutics by 12.3% in the third quarter. BOKF NA now owns 7,834 shares of the biotechnology company’s stock worth $4,245,000 after purchasing an additional 857 shares in the last quarter. Finally, Asset Management One Co. Ltd. grew its stake in United Therapeutics by 1.9% in the third quarter. Asset Management One Co. Ltd. now owns 23,166 shares of the biotechnology company’s stock worth $12,553,000 after purchasing an additional 424 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
Key Stories Impacting United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: The FDA cleared United Therapeutics to begin a clinical trial of its inhaled treprostinil-iloprost combination, or Treprostinil-Iloprost SMI, for pulmonary arterial hypertension. The therapy could expand the company’s PAH pipeline, although the trial remains an early-stage development milestone. FDA clearance article
- Positive Sentiment: The company’s board recently authorized a $2 billion share-repurchase program, potentially reducing shares outstanding by as much as 8.3%. Buybacks can support per-share earnings and signal management views the stock as undervalued.
- Positive Sentiment: JPMorgan maintained an “overweight” rating and continues to see upside despite lowering its price target to $695 from $710. The broader analyst consensus remains “Moderate Buy,” with an average target of $666.50. JPMorgan analyst action
- Neutral Sentiment: United Therapeutics is approaching its next earnings report. Recent coverage highlights investor interest ahead of the release, while the company’s prior quarter showed stronger-than-expected earnings but revenue below estimates and a year-over-year decline. Earnings outlook article
- Negative Sentiment: Zacks expects earnings to decline in the upcoming report and says United Therapeutics lacks the combination of factors typically associated with a likely earnings beat. That raises near-term uncertainty for a stock trading close to its 52-week high. Zacks earnings expectations
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares worth roughly $5.6 million, reducing her ownership by 2.84%. The transactions were disclosed as part of a prearranged plan, which lessens—but does not eliminate—the negative signaling effect of insider selling.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
Featured Articles
- Five stocks we like better than United Therapeutics
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
